Document Type

Letter to the Editor

Publication Date

8-5-2020

Comments

This article is the author's final published version in Hematology, Transfusion and Cell Therapy, August 2020

The published version is available at https://doi.org/10.1016/j.htct.2020.06.009. Copyright © Queiroz et al.

Abstract

Women with sickle cell anemia (SCA) require special attention for myriad obstetric and gynecologic issues associated with this complex hematologic disorder. These affect all aspects of female life from menarche through menopause. Information regarding obstetric and gynecologic complications of sickle cell disease (SCD), with a few exceptions, is based primarily on observational, anecdotal, retrospective, or cohort studies that may not reflect current aspects of obstetric care.1 Similarly, there are no recent reports about menopause (also known as climacteric) in women with SCA. The fact that life expectancy of women with SCA was determined to be 46–48 years2 delayed studies about menopause. The recent improved survival of patients with SCA resulted in women reaching the age that is usually associated with the onset of menopause. The purpose of this letter is to determine if the onset of menopause is early or late in women with SCA and if hydroxyurea affects the onset of menopause.

Creative Commons License

Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.

Language

English

Download

Included in

Hematology Commons

Share

COinS